Anabolic-androgenic steroid therapy in the treatment of chronic diseases

被引:216
作者
Basaria, S [1 ]
Wahlstrom, JT [1 ]
Dobs, AS [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA
关键词
D O I
10.1210/jc.86.11.5108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to review the preclinical and clinical literature relevant to the efficacy and safety of anabolic androgen steroid therapy for palliative treatment of severe weight loss associated with chronic diseases. Data sources were published literature identified from the Medline database from January 1966 to December 2000, bibliographic references, and textbooks. Reports from preclinical and clinical trials were selected. Study designs and results were extracted from trial reports. Statistical evaluation or meta-analysis of combined results was not attempted. Androgenic anabolic steroids (AAS) are widely prescribed for the treatment of male hypogonadism; however, they may play a significant role in the treatment of other conditions as well, such as cachexia associated with human immunodeficiency virus, cancer, burns, renal and hepatic failure, and anemia associated with leukemia or kidney failure. A review of the anabolic effects of androgens and their efficacy in the treatment of these conditions is provided. In addition, the numerous and sometimes serious side effects that have been known to occur with androgen use are reviewed. Although the threat of various side effects is present, AAS therapy appears to have a favorable anabolic effect on patients with chronic diseases and muscle catabolism. We recommend that AAS can be used for the treatment of patients with acquired immunodeficiency syndrome wasting and in severely catabolic patients with severe burns. Preliminary data in renal failure-associated wasting are also positive. Advantages and disadvantages should be weighed carefully when comparing AAS therapy to other weight-gaining measures. Although a conservative approach to the use of AAS in patients with chronic diseases is still recommended, the utility of AAS therapy in the attenuation of severe weight loss associated with disease states such as cancer, postoperative recovery, and wasting due to pulmonary and hepatic disease should be more thoroughly investigated.
引用
收藏
页码:5108 / 5117
页数:10
相关论文
共 128 条
[1]  
AMORY JK, 1999, P 81 ANN M END SOC S
[2]   ULTRASTRUCTURAL AND MORPHOMETRIC INVESTIGATIONS ON THE EFFECTS OF TRAINING AND ADMINISTRATION OF ANABOLIC-STEROIDS ON THE MYOCARDIUM OF GUINEA-PIGS [J].
APPELL, HJ ;
HELLERUMPFENBACH, B ;
FERAUDI, M ;
WEICKER, H .
INTERNATIONAL JOURNAL OF SPORTS MEDICINE, 1983, 4 (04) :268-274
[3]  
ARIAS IM, 1962, PROTEIN METABOLISM, P434
[4]  
ARNOLD GL, 1979, AM J GASTROENTEROL, V71, P213
[5]   ANDROGEN DEPENDENCY IN ACQUIRED APLASTIC-ANEMIA [J].
AZEN, EA ;
SHAHIDI, NT .
AMERICAN JOURNAL OF MEDICINE, 1977, 63 (02) :320-324
[6]   Risks versus benefits of testosterone therapy in elderly men [J].
Basaria, S ;
Dobs, AS .
DRUGS & AGING, 1999, 15 (02) :131-142
[7]   TESTOSTERONE BUCICLATE (20 AET-1) IN HYPOGONADAL MEN - PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NEW LONG-ACTING ANDROGEN ESTER [J].
BEHRE, HM ;
NIESCHLAG, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (05) :1204-1210
[8]   Oxandrolone in AIDS-wasting myopathy [J].
Berger, JR ;
Pall, L ;
Hall, CD ;
Simpson, DM ;
Berry, PS ;
Dudley, R .
AIDS, 1996, 10 (14) :1657-1662
[9]   HEPATOMA AND PELIOSIS HEPATIS DEVELOPING IN A PATIENT WITH FANCONIS ANEMIA [J].
BERNSTEIN, MS ;
HUNTER, RL ;
YACHNIN, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1971, 284 (20) :1135-+
[10]   Effects of testosterone replacement with a nongenital, transdermal system, androderm, in human immunodeficiency virus-infected men with low testosterone levels [J].
Bhasin, S ;
Storer, TW ;
Asbel-Sethi, N ;
Kilbourne, A ;
Hays, R ;
Sinha-Hikim, I ;
Shen, RQ ;
Arver, S ;
Beall, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (09) :3155-3162